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Learning objectives: 
 
1. To recognise that acute myocardial ischaemia/reperfusion injury is a neglected 
therapeutic target for cardioprotection that is responsible for the ongoing morbidity 
and mortality of patients with ischaemic heart disease. 
 
2. To be aware that cardiac bypass surgery and STEMI are the major clinical settings 
in which the heart is subjected to acute ischaemia/reperfusion injury. 
 
3. To be familiar with the concept of ‘ischaemic conditioning’, in which the heart is 
protected against acute ischaemia/reperfusion injury by subjecting it to cycles of 
brief ischaemia and reperfusion, a therapeutic strategy which has been 
demonstrated in proof-of-concept studies to be beneficial in patients with ischaemic 
heart disease. 
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1. INTRODUCTION - THE NEED FOR CARDIOPROTECTION 
Ischaemic heart disease (IHD) is the leading cause of death and disability worldwide. 
Despite current therapies, patients still experience significant morbidity and mortality when 
undergoing cardiac bypass surgery or when presenting with an ST-segment elevation 
myocardial infarction (STEMI). This is partly attributed to the detrimental effects of acute 
ischaemia/reperfusion injury (IRI) on the heart, which in combination mediate 
cardiomyocyte death, resulting in impaired left ventricular (LV) systolic function and 
increased risk of heart failure. Although a number of strategies exist for reducing the 
ischaemic component of acute IRI injury in cardiac bypass surgery (such as cardioplegia 
and hypothermia) and STEMI (such as prompt reperfusion with primary percutaneous 
intervention - PPCI), paradoxically, reperfusing previously ischaemic myocardium leads to 
further cardiomyocyte death – termed ‘myocardial reperfusion injury’ and for which there is 
currently no effective therapy. Therefore, novel therapeutic interventions are required to 
protect the heart from acute IRI in these clinical settings in order to improve clinical 
outcomes. In this regard, ‘ischaemic conditioning’, in which the heart is rendered tolerant 
to acute IRI by subjecting it to cycles of brief ischaemia and reperfusion, provides an 
endogenous form of cardioprotection. In this article, we review the role for ischaemic 
conditioning as a therapeutic strategy for attenuating cardiomyocyte death, preserving 
myocardial function, and improving clinical outcomes in patients subjected to acute 
myocardial IRI. 
 
2. MYOCARDIAL REPERFUSION INJURY – A NEGLECTED THERAPEUTIC TARGET 
Although myocardial reperfusion is essential to salvage viable myocardium following the 
onset of acute myocardial ischaemia, the restoration of coronary blood flow comes at a 
price, paradoxically inducing myocardial injury and cardiomyocyte death – termed 
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‘myocardial reperfusion injury’. Four types of myocardial reperfusion injury have been 
described:  
1. Reperfusion-induced arrhythmias: These occur on reperfusing previously ischaemic 
myocardium and comprise idioventricular rhythm and ventricular arrhythmias, the 
majority of which are self-terminating or are easily treated. 
2. Myocardial stunning: This refers to the reversible contractile dysfunction that occurs on 
reperfusing acute ischaemic myocardium and is believed due to be due to myocardial 
oxidative stress and intracellular calcium overload. 
3. Coronary no-reflow and microvascular obstruction: Coronary no-reflow is indicative of 
underlying microvascular obstruction (MVO) – defined as the “inability to reperfuse a 
previously ischaemic region”1. MVO is present on cardiovascular magnetic resonance 
imaging (CMR) in 40 to 60% of PPCI patients, despite the presence of normal coronary 
flow (TIMI 3) within the infarct-related artery post-PPCI2 3. The presence of MVO is 
associated with adverse LV remodelling and worse clinical outcomes post-PPCI.  
4. Lethal myocardial reperfusion injury: Ischaemia/Reperfusion induces cytosolic and 
mitochondrial calcium overload, oxidative stress, rapid restoration in intracellular pH, 
which on a background of relative adenosine triphosphate (ATP) depletion, culminates 
in the opening of the mitochondrial permeability transition pore (MPTP) and irreversible 
cardiomyocyte hypercontracture – the hallmark of lethal myocardial reperfusion injury. 
Cardiomyocytes that were still viable at the end of the index ischaemic insult 
undergoes necrosis and this accounts for up to 50% of the final MI size, thereby 
mitigating the benefits of reperfusion, and making lethal myocardial reperfusion injury a 
therapeutic target for cardioprotection (Figure 1).  
 
Crucially, there is currently no effective therapy for reducing either MVO or lethal 
myocardial reperfusion injury. In the following sections we review the therapeutic potential 
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of ischaemic conditioning, a collective term given to the different forms of endogenous 
cardioprotection, which have been described, and these include ischaemic 
preconditioning, ischaemic postconditioning and remote ischaemic conditioning.  
 
3. ISCHAEMIC PRECONDITIONING – LIMITED CLINICAL APPLICATION 
In 1986, Murry et al4 made the intriguing observation that following an acute coronary 
artery occlusion the resultant myocardial infarct (MI) size could be significantly reduced by 
‘preconditioning’ the heart with brief episodes of ischaemia and reperfusion. In that 
landmark experimental study, four cycles of 5-minutes alternating left anterior descending 
(LAD) coronary artery occlusion and reflow applied immediately prior to a 90-minutes LAD 
occlusion and a 3-days reperfusion period, led to a 25% reduction in MI size in the canine 
heart4. This endogenous form of cardioprotection, which was termed ischaemic 
preconditioning (IPC), has been shown to be ubiquitous in several other organs and all 
species tested (reviewed in 5 6). The IPC stimulus is known to elicit two windows of 
cardioprotection, the first one occurring immediately and lasting 2-3 hours, and the second 
one appearing 12-24 hours later, and lasting up to 72 hours. In several clinical scenarios 
the heart is able to protect itself by IPC – e.g. (1) ‘Warm-up angina’ refers to the 
phenomenon in which a patient with stable IHD is able to exercise more following an 
episode of angina followed by a period of rest7; (2) ‘Pre-infarct angina’ refers to the 
cardioprotective effects of an episodes of angina immediately prior to an MI resulting in 
smaller MI size and better clinical outcomes8. As a cardioprotective strategy for protecting 
the heart against acute IRI, its clinical application has been limited by the need to apply 
the IPC stimulus directly to the heart, and prior to the index ischaemia, which cannot be 
predicted in acute MI patients. In this regard, the discovery of ischaemic postconditioning 
has provided a cardioprotective strategy which can be applied at the time of reperfusion to 
protect the heart against acute IRI. 
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4. ISCHAEMIC POSTCONDITIONING – PROTECTION AT TIME OF REPERFUSION 
In 2003, Zhao et al 9 discovered that by interrupting myocardial reperfusion with several 
short-lived episodes of myocardial ischaemia could reduce MI size to a similar extent as 
IPC – a phenomenon which has been termed ‘ischaemic postconditioning’ (IPost)6 10. 
They9 found that by applying three cycles of 30-seconds LAD coronary artery occlusion 
and reflow at the onset of myocardial reperfusion could reduce MI size by 44% in the 
canine heart9. The idea of modifying reperfusion as a strategy to limit MI size was first 
proposed in the 1980s and 1990s using gentle11 and gradual12 reperfusion instead of 
sudden reperfusion. The discovery of IPost as a therapeutic strategy which could be 
applied at the onset of myocardial reperfusion has rekindled interest in lethal myocardial 
reperfusion injury as a target for cardioprotection, and was rapidly translated into the 
clinical setting within two years of discovery13. It has also provided confirmatory evidence 
for the existence of lethal myocardial reperfusion injury in man. However, both IPC and 
IPost require an intervention applied to the heart directly, which may not always be 
feasible depending on the clinical situation, and therefore, the strategy of remote 
ischaemic conditioning, in which the cardioprotective stimulus is applied to an organ or 
tissue away from the heart is vastly more attractive as a clinical application.  
 
5. REMOTE ISCHAEMIC CONDITIONING – CARDIOPROTECTION MADE EASY 
In 1993, Przyklenk et al14 made the interesting observation that the cardioprotective effect 
of IPC was not restricted to one particular coronary artery territory as it could be 
transferred to another coronary artery territory. This gave rise to the concept of ‘remote 
ischaemic conditioning’ (RIC), the term given to the cardioprotection induced by applying 
cycles of brief ischaemia and reperfusion to an organ or tissue away from the heart. Using 
the canine heart, these authors found that brief occlusions and reflow in the circumflex 
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coronary artery were able to reduce MI size by 63% following LAD coronary artery 
occlusion14. This idea was soon extended beyond the heart with the demonstration that 
the RIC stimulus (cycles of brief ischaemia and reperfusion) could be applied to the kidney 
to limit MI size, giving rise to the concept of inter-organ protection against acute IRI15. Two 
key properties of RIC have facilitated its translation into the clinical setting:  
(1) Feasibility: The discovery in an experimental animal MI model that the RIC stimulus 
could be applied to the hind limb to protect the heart against acute IRI16 17, and the finding 
that the RIC stimulus could be delivered non-invasively in human volunteers by simply 
inflating a blood pressure cuff on the upper arm to induce cycles of brief ischaemia and 
reperfusion18, has greatly increased its feasibility in the clinical setting.  
(2) Flexibility: The application of IPC and IPost are restricted in terms of their ‘timings’, as 
the protective stimulus has to be applied either prior to ischaemia or at the onset of 
reperfusion, respectively) and ‘target’ (the protective stimulus has to be applied to the 
heart directly), whereas RIC can be applied at any time (either prior to, after the onset of, 
or at the end of ischaemia) and to an organ or tissue away from the heart, thereby making 
it much more flexible as a cardioprotective strategy (Figure 2).   
Therefore, most clinical studies applying RIC as a cardioprotective strategy have used 
cycles of brief ischaemia and reperfusion in the upper or lower limb (henceforth referred to 
as limb RIC).  
 
6. OVERVIEW OF MECHANISMS UNDERLYING ISCHAEMIC CONDITIONING 
The mechanisms underlying ischaemic conditioning are rather complex and have been the 
subject of intensive investigation over the last 20 to 30 years (for comprehensive reviews 
please see 5 6 19 20). With respect to IPC and IPost, the current paradigm proposes that the 
cycles of brief ischaemia and reperfusion, which make up the protective stimulus generate 
autacoids in the interstitium which then activate a number of signal transduction pathways 
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by binding to their respective receptors on the cardiomyocyte plasma membrane. This in 
turn results in the recruitment of a number of pro-survival protein kinase pathways (such 
as the Reperfusion Injury Salvage Kinase [RISK]21 22, Survivor Activator Factor 
Enhancement [SAFE]23, and cGMP-PKG pathways24), which converge on and protect 
mitochondria from dysfunction induced by acute IRI. However, it is important to appreciate 
that there are some differences between IPC and IPost in terms of it signalling 
components. With IPC there is an additional signalling pathway responsible for the 
‘memory’ effect of classical IPC (the activation of protein kinases such as protein kinase C) 
and of the second window of protection (the transcription of new proteins such as 
cyclooxygenase-2, inducible nitric oxide synthase and so on)6 20. The mechanisms 
underlying RIC are even more complex given the added dimension of having to convey 
the cardioprotective signal from the remote organ or tissue to the heart. Once at the heart, 
the signalling pathways alluded to above for IPC and IPost are also recruited by RIC. The 
details of the pathway linking the remote organ or tissue to the heart remain unresolved, 
but are believed to involve the release of local autacoids stimulating the sensory afferent 
neural pathway in the remote organ or tissue leading to the production of a circulating 
transferrable blood-borne factor(s), which is able to confer cross-species cardioprotection.  
The identity of the cardioprotective factor(s) remains unknown, but is probably a peptide 
<30 kilodaltons in size (reviewed in 25 26). 
 
7. CLINICAL APPLICATION OF ISCHAEMIC CONDITIONING 
Ischaemic conditioning has been investigated in several clinical settings in which the heart 
is subjected to acute myocardial IRI including cardiac bypass surgery, elective 
percutaneous coronary intervention (PCI) and PPCI (Figure 2). 
 
7.1. Cardiac bypass surgery as a clinical setting for cardioprotection 
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In patients undergoing cardiac bypass surgery the heart is subjected to global ischaemic 
injury (when the aorta is clamped and the heart is put onto cardiopulmonary bypass) 
followed by global reperfusion injury (when the aorta is unclamped and the heart is taken 
off cardiopulmonary bypass)27. However, acute IRI is not the only cause of myocardial 
injury during cardiac bypass surgery as direct handling of the heart, coronary embolisation, 
and the inflammatory response to cardiopulmonary bypass can all contribute. The 
perioperative myocardial injury (PMI) which occurs during cardiac bypass surgery can be 
quantified by measuring serum cardiac enzymes (Creatine Kinase MB isoenzyme, 
Troponin T and I)28 29, and can be detected as late gadolinium enhancement on 
cardiovascular magnetic resonance imaging (CMR)30. Given that the presence of PMI has 
been associated with worse clinical outcomes post-cardiac surgery28 29, the measurement 
of serum cardiac enzymes has been used as a surrogate endpoint to assess the 
cardioprotective efficacy of novel therapies in patients undergoing cardiac bypass surgery.  
 
IPC and IPost in cardiac bypass surgery 
IPC was the first cardioprotective strategy to be investigated in the setting of cardiac 
bypass surgery. In 1993, Yellon’s group31 first demonstrated that brief episodes of global 
ischaemia induced by clamping and declamping the aorta prior to cardiopulmonary bypass 
preserved myocardial ATP levels in patients with IHD. Since then a number of studies 
have investigated the role of IPC as a cardioprotective strategy in cardiopulmonary bypass 
surgery. In a recent meta-analysis it was shown that IPC significantly reduced ventricular 
arrhythmias, decreased inotrope requirements and shortened the intensive care unit 
stay32. However, despite these potential beneficial effects, the need to intervene on the 
heart directly and the risk of embolisation arising from clamping an atherosclerotic aorta 
have prevented IPC from being adopted in this clinical setting.  
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Using a similar approach to cardioprotection at the time of aorta unclamping it has 
been reported that IPost induced by re-clamping and declamping the aorta to stutter global 
myocardial reperfusion attenuated perioperative myocardial injury in terms of serum 
cardiac enzyme release33. There is the potential to apply this cardioprotective strategy to 
children (in whom the aorta is not yet atherosclerotic) undergoing cardiopulmonary bypass 
surgery to correct congenital cardiac defects34.    
 
Limb RIC in cardiac bypass surgery 
Limb RIC was first demonstrated to show benefit in the clinical setting of cardiac bypass 
surgery in 2006 by Cheung et al35 in children undergoing corrective cardiac surgery for 
congenital heart defects. Subsequent studies have reported beneficial effects of RIC in 
adult patients undergoing coronary artery bypass graft surgery (CABG) and/or valve 
surgery in terms of attenuated perioperative myocardial injury as evidenced by decreased 
serum cardiac enzyme release (Table 1). However, there have been several neutral 
studies36-38 including at least one very large study39. The reasons for this discrepancy are 
not clear but may relate to the following factors: patient selection (CABG vs valve surgery, 
stable vs unstable IHD patients); timing of the limb RIC protocol (prior to vs after surgical 
incision); blinding of the RIC protocol (proper vs limited blinding); the intensity of the RIC 
protocol (3 vs 4 cycles of limb RIC and inflation of cuff to 200mmHg vs 15mmHg above 
systolic blood pressure); and the presence of confounding factors (Table 5). The results of 
several recent meta-analyses have confirmed the cardioprotective effects of RIC in this 
clinical setting in terms of attenuating perioperative myocardial injury40 41. The ongoing 
RIPHeart42 and ERICCA43 multicentre clinical trials, which are currently investigating the 
effect of RIC on clinical outcomes post cardiac bypass surgery (Table 1), should hopefully 
provide definitive evidence of the cardioprotective effects of RIC in this clinical setting.   
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7.2. Elective PCI as a clinical setting for cardioprotection 
Ischaemic conditioning has been investigated as a cardioprotective strategy for protecting 
the heart against periprocedural myocardial injury in patients undergoing elective PCI. It is 
important to appreciate that PCI-related injury, which occurs in about 20 to 30% of patients 
undergoing elective PCI and measured by the release of serum cardiac enzymes, is not 
due to acute IRI, but mainly by acute ischaemic injury (distal branch occlusions, and 
coronary embolisation) - complications which are more frequent following multi-vessel and 
complex PCI44. Limb RIC administered prior to elective PCI has been reported to be 
beneficial in IHD patients, in terms of reducing serum levels of cardiac enzymes (Table 2), 
although there have been a number of neutral studies45 46 and one negative study47. The 
reasons for this discrepancy are not clear but may relate to the following factors: the 
setting itself (acute IRI not a major component of myocardial injury during elective PCI); 
patient selection (stable vs unstable IHD patients); the timing of RIC in relation to PCI 
procedure (prior to vs after) and the PCI procedure itself (simple vs multi-vessel or 
complex PCI). A recent meta-analysis has suggested that limb RIC may be beneficial if 
lower limb RIC is used and in the setting of multi-vessel or complex PCI48.  
 
7.3. PPCI as a clinical setting for cardioprotection 
For patients presenting with STEMI, the most effective therapy for limiting MI size and 
preserve LV systolic function is myocardial reperfusion by PPCI. However, the restoration 
of coronary blood flow in the infarct-related artery induces myocardial reperfusion injury, 
thereby providing a target for cardioprotection for ischaemic conditioning strategies such 
as IPost and RIC.    
 
IPost in STEMI patients 
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IPost was rapidly translated into the clinical setting by Staat et al in 2005 only 2 years after 
its discovery in the original animal experimental study13. They demonstrated in a small 
proof-of-concept study of 30 patients that IPost could reduce enzymatic MI size by 36% 
(Table 3). The IPost protocol was applied following direct stenting of the infarct-related 
artery by inflation of the angioplasty balloon to low pressure upstream of the stent to 
interrupt coronary flow for one minute followed by deflation of the angioplasty balloon for 
one minute to allow coronary reflow and repeated 4 times in total. A number of clinical 
studies have gone on to confirm the cardioprotective effect of IPost using 
echocardiographic, myocardial SPECT and CMR endpoints (Table 3). However, not all the 
studies have been positive49 50, and the reasons for this are not clear but may be due to a 
number of factors including: patient selection (only patients with complete occlusion of the 
infarct-related artery and no coronary collateralisation should be included), the stenting 
technique (most benefit seen with direct stenting), the IPost protocol itself (which should 
not be delivered within the stent); the endpoints used to assess cardioprotection (ST-
segment resolution vs MI size). The results of recent meta-analyses of IPost in PPCI 
patients have also produced mixed results51-54. Whether IPost can actually improve clinical 
outcomes following PPCI is currently being investigated in the DANAMI-3 trial 
(ClinicalTrials.gov Identifier: NCT01435408)(Table 3).  
 
Limb RIC in STEMI patients 
Several proof-of-concept studies have reported cardioprotective effects with limb RIC in 
STEMI patients treated by PPCI (Table 3). It appears to be effective when given in the 
ambulance by paramedics55, on arrival at the hospital prior to PPCI56 57, and even at the 
onset of reperfusion at the time of PPCI58. Whether limb RIC can improve clinical 
outcomes in PPCI patients is currently being investigated in the ERIC-PPCI and CONDI2 
trials (ClinicalTrials.gov Identifier: NCT01857414), which are investigation, in collaboration, 
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whether RIC can reduce the rates of cardiac death and hospitalisation for heart failure at 
12 months.     
 
Pharmacological conditioning – mimicking ischaemic conditioning 
The elucidation of the signal transduction pathways underlying ischaemic conditioning 
have resulted in the identification of new targets for cardioprotection, some of which can 
be modulated by pharmacological agents (reviewed in 59 60). In this regard, the most 
promising of these pharmacological conditioning strategies include atrial natriuretic 
peptide61, cyclosporin-A (CsA)62, exenatide63, and metoprolol64, all of which have been 
reported in proof-of-concept clinical studies to reduce MI size and preserve LV systolic 
function (Table 4). Whether CsA therapy can improve clinical outcomes post-PPCI is 
currently being tested in two clinical outcome studies (the CYCLosporinE A in Reperfused 
Acute Myocardial Infarction (CYCLE) (ClinicalTrials.gov NCT01650662) and Cyclosporine 
and Prognosis in Acute Myocardial Infarction Patients (CIRCUS) (ClinicalTrials.gov 
NCT01502774) multi-centre randomised clinical trials. 
 
8. NEW AVENUES FOR ISCHAEMIC CONDITIONING 
8.1. Other clinical settings of acute myocardial IRI  
There are other clinical settings in which acute myocardial IRI is a critical determinant of 
outcome. In patients having a cardiac arrest the whole body including the heart is 
subjected to acute global ischaemia, and in those patients which are successfully 
resuscitated, the whole body is then subjected to acute global reperfusion injury. Whether 
limb RIC is a therapeutic option in patients who are successfully resuscitated following a 
cardiac arrest remains to be tested. The added benefit of limb RIC in this setting is multi-
organ protection against acute IRI.  
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For patients undergoing cardiac transplantation acute IRI is a major determinant of 
graft dysfunction post-transplantation. In this setting, the heart is subjected to global 
ischaemic injury as it is removed from the donor, followed by global reperfusion injury as it 
is transplanted into the recipient. In this setting there is the opportunity to perform limb RIC 
to the donor prior to organ harvesting and to the recipient prior to transplantation, but 
whether this approach is beneficial remains to be tested.  
 
8.2. Limb RIC and cardiac function 
A number of clinical studies are investigating the cardioprotective effects of limb RIC on 
cardiac function. Limb RIC has been reported to attenuate ST-segment depression and 
prevent myocardial stunning in chronic renal failure patients undergoing haemodialysis 
during which the heart is subjected to repeated bouts of acute myocardial ischemia 
resulting in myocardial stunning and chronic LV systolic impairment 65.  
Whether repeated episodes of limb RIC, applied as a daily therapy, is beneficial in 
the clinical setting is not known. One experimental study demonstrated that repeating limb 
RIC daily for 28 days prevented adverse post-MI LV remodelling in the rat heart66. There 
are currently two clinical studies investigating the effect of daily RIC continued for 4 weeks 
on post-MI LV remodelling (Daily REmote Ischaemic Conditioning following Acute 
Myocardial Infarction (DREAM, ClinicalTrials.gov Identifier: NCT01664611) and the 
Chronic Remote Ischemic Conditioning to Modify Post-MI Remodeling (CRIC-RCT; 
ClinicalTrials.gov Identifier:NCT01817114) trials. The CONDI-HF study (ClinicalTrials.gov 
Identifier:NCT02248441) is currently investigating the effect of daily RIC on LV ejection 
fraction in chronic heart failure patients.  
 
8.3. Increasing exercise performance by limb RIC 
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Interestingly, limb RIC has been reported to improve exercise performance in elite 
swimmers67, presumably by rendering skeletal muscle more tolerant to acute ischaemia, 
although the actual mechanism is not clear. In the setting of heart failure however, limb 
RIC failed to improve exercise capacity and oxygen consumption, with the suggestion that 
heart failure patients were already chronically preconditioned, as plasma dialysate 
obtained from both sham and RIC patients reduced murine MI size compared to plasma 
dialysate from historical healthy controls 68.   
 
8.4. Limb RIC protection of other organs 
The key advantage of limb RIC as a therapeutic strategy is that it offers multi-organ 
protection against acute IRI. As such limb RIC has been shown to be beneficial in a 
number of non-cardiac organs including the brain (against acute ischaemic stroke69), the 
kidney (protection against acute kidney injury induced by cardiac bypass surgery38 70 71, 
and induced by contrast following coronary angiography72) and the liver (during acute liver 
resection [ClinicalTrials.gov Identifier: NCT007965880] and liver transplantation [Remote 
Ischaemic PreCOnditioning in Liver Transplant or RIPCOLT. The recently completed 
REnal Protection Against Ischaemia-Reperfusion in transplantation (REPAIR) trial 
(ISRCTN30083294) has found that limb RIC of both the donor and recipient preserved 
estimated glomerular filtration rate of the transplanted kidney at 6 months in recipient 
patients undergoing live-donor related renal transplantation, suggesting limb RIC to be a 
potential therapeutic strategy for preserving renal graft function post-transplantation.  
 
9. OPTIMISING THE TRANSLATION OF CARDIOPROTECTION 
The field of cardioprotection has a chequered history with a disappointing large number of 
neutral clinical studies in which a novel cardioprotective therapy has failed to improve 
clinical outcomes in IHD patients subjected to acute IRI. The failure to translate the large 
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number of cardioprotective therapies discovered in laboratory studies into patient benefit 
has been the subject of several recent articles 73-76- the major issues are highlighted in 
Table 5.      
 
10. SUMMARY AND CONCLUSIONS  
Ischaemic conditioning is an endogenous form of cardioprotection which can be elicited by 
cycles of brief ischaemia and reperfusion to the heart directly or to an organ or tissue away 
from the heart. A number of proof-of-concept clinical studies have shown beneficial effects 
with ischaemic conditioning in the settings of cardiac bypass surgery, elective PCI and 
PPCI, with reduced myocardial injury and preservation of cardiac function. Whether 
ischaemic conditioning can actually improve clinical outcomes in CABG and PPCI patients 
is currently being investigated in several large multi-centre randomised clinical trials. As a 
result, in the next couple of years we should know whether ischaemic conditioning could 
benefit IHD patients in terms of reducing morbidity and mortality and potentially change 
clinical practice.  
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Figure legends 
Figure 1 
The clinical impact of myocardial reperfusion injury in reperfused STEMI patients 
This hypothetical scheme depicts the magnitude and clinical impact of myocardial 
reperfusion injury on patients with ischaemic heart disease who are subjected to acute 
ischaemia/reperfusion injury. The thick blue curve shows the extent of myocardial salvage 
(which equates to the area-at-risk subtract the myocardial infarct size and is expressed as 
the % of the left ventricular volume) in a theoretical patient presenting with an acute ST-
segment elevation myocardial infarction (STEMI) reperfused by primary percutaneous 
coronary intervention (PPCI) or thrombolysis – as expected in the absence of reperfusion 
the extent of myocardial salvage declines with time. Although myocardial reperfusion is 
essential for myocardial salvage following a STEMI, the process of restoring coronary 
blood flow within the infarct-related artery, can paradoxically induce cardiomyocyte death – 
a phenomenon which has been termed ‘myocardial reperfusion injury’. As a result, 
following reperfusion, the extent of myocardial salvage is actually smaller than expected 
given the duration of acute myocardial ischaemia – this attenuation in myocardial salvage 
is due to the presence of myocardial reperfusion injury, which can contribute up to 50% of 
the final myocardial infarct size. 
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Figure 2 
Ischaemic conditioning in the clinical setting 
This figure illustrates the variety of clinical settings in which ischaemic conditioning has 
been tested (in orange) including: cardiac bypass surgery, elective percutaneous coronary 
intervention (PCI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients 
undergoing PCI, and STEMI patients. There is the potential to investigate the role of 
ischaemic conditioning in other clinical settings (in yellow) such as heart transplantation, 
heart failure and cardiac arrest. The term ischaemic conditioning encompasses a number 
of endogenous forms of cardioprotection including ischaemic preconditioning (IPC, which 
has to be delivered within 2-3 hours of the index ischaemia), ischaemic postconditioning 
(IPost, which has to be delivered in the first minute of reperfusion) and remote ischaemic 
conditioning (RIC, using transient limb ischaemia and reperfusion). RIC can be divided 
according to the timing of the intervention into remote ischaemic preconditioning (RIC 
stimulus applied prior to index ischaemia), RIPerC (RIC stimulus applied after the onset of 
index ischaemia but prior to reperfusion) and RIPost (RIC stimulus applied at the onset of 
reperfusion).  
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Table 1: Major clinical studies investigating limb RIC in cardiac bypass surgery  
Study RIC protocol 
 
Number Main outcomes Comments 
Cheung et al 
200635 
 
Four x 5 minutes thigh cuff 
inflations/deflations  
 
37 Smaller peak Trop T, 
less inotrope support 
and lower airway 
pressures 
First study to report 
beneficial effect of 
limb RIC in CABG 
 
Hausenloy et al 
200777 
Three x 5 minutes upper arm 
cuff inflations/deflations  
 
53 43% reduction in 72 
hr AUC Trop-T 
First study to report 
beneficial effect of 
limb RIC patients 
undergoing CABG 
 
Candilio et al 
201471 
Two x 5 minutes 
simultaneous upper arm and 
thigh cuff inflations/deflations  
180 27% less 72 hr AUC 
Trop T. 54% Less AF 
48% Less AKI and 1 
day less ICU stay 
First study to report 
beneficial effect of 
limb RIC on short-
term clinical 
outcomes 
 
Heusch et al 
201378 
Three x 5 minutes upper arm 
cuff inflations/deflations  
329 21% less 72 hr AUC 
Trop I. 73% reduction 
in all-cause mortality 
First study to report 
beneficial effect of 
limb RIC on long-term 
clinical outcomes. 
 
Ongoing studies 
 
Meybohm et al  
RIPHEART42 
Four x 5 minutes cycles of 
upper arm cuff 
inflation/deflation 
2070 
 
Primary endpoint of 
death, non-fatal MI, 
stroke, AKI at 30 days 
First study which will 
test effect of RIC on 
30 days primary 
endpoint following 
CABG 
Results available 
March 2015 
 
Hausenloy et al  
ERICCA43 
 
Four x 5 minutes cycles of 
upper arm cuff 
inflation/deflation 
1610 
 
Primary endpoint of 
death, non-fatal MI, 
revascularisation, 
stroke at 12 months 
First study which will 
test effect of RIC on 
12 months primary 
endpoint following 
CABG 
Results available 
March 2015 
 
RIC: remote ischaemic conditioning; Trop T: troponin T; CABG: cardiac bypass surgery; AUC: area under curve; AF: atrial fibrillation; 
AKI: acute kidney injury; ICU: intensive care unit; MI: myocardial infarct 
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Table 2: Major clinical studies investigating limb RIC in elective PCI 
Clinical study RIC protocol 
 
Number 
of 
patients 
Outcome Comments 
Hoole et al 
200979 
Three x 5 minutes upper arm 
cuff inflations/deflations 
immediately prior to PCI 
 
242 63% reduction in 
median Trop I 
First study to test 
effect of limb RIC in 
PCI 
Davies et al 
201380 
 
Three x 5 minutes upper arm 
cuff inflations/deflations 
immediately prior to PCI 
 
192 42% reduction in  all-
cause mortality, 
nonfatal MI, TIA or 
stroke, HHF at 6 
years 
First study to test 
effect of limb RIC on 
long-term clinical 
outcomes following 
PCI 
 
Zografos et al 
201481 
One x 5 minutes upper arm 
cuff inflations/deflations 
Immediately prior to PCI  
94 80% reduction in 24 
hr serum levels of 
Trop I. Also reduced 
incidence of PCI-
related MI by 56%. 
 
First study to test 
effect of one cycle of 
limb RIC 
Liu et al 201482 
 
Three x 5 minutes upper arm 
cuff inflations/deflations 
18 hours prior to PCI 
200 40-60% reduction in 
24 hr serum levels of 
Trop I and CK-MB. 
Also less chest pain 
and ST-segment 
deviation with PCI. 
 
First study to test 
effect of second 
window of protection 
of  limb RIC 
EURO-CRIPS 
83 
Three x 5 minutes upper arm 
cuff inflations/deflations 
immediately prior to PCI 
 
Planned 
 Also investigating the 
effect of limb RIC on 
contrast-induced AKI 
 
RIC: remote ischaemic conditioning; PCI: percutaneous coronary intervention, Trop I: troponin I; MI: myocardial infarction; TIA: transient 
ischaemic attack; HHF: hospitalisation for heart failure; CK-MB: creatine kinase MB isoenzyme; AKI: acute kidney injury  
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Table 3: Major clinical studies investigating IPost and limb RIC in STEMI patients 
Clinical study Treatment protocol 
 
Number of 
patients 
Outcome Comments 
Ischaemic postconditioning in STEMI patients 
 
Staat et al 
200513  
Four x 60 seconds 
angioplasty balloon 
inflations/deflations 
30  
 
36% reduction in 72 
hours AUC CK 
 
First study to report 
beneficial effect of 
IPost in PPCI patients 
 
Thibault et al 
200884  
Four x 60 seconds 
angioplasty balloon 
inflations/deflations  
38 
 
41% reduction in 72 
hours AUC CK-MB 
39% reduction in MI 
size at 6 months by 
SPECT 
LVEF improved by 7% 
echocardiogram at one 
year 
 
First study to report 
long-term 
cardioprotective 
effects of IPost in 
PPCI patients 
 
Lonborg et al 
201085  
Four x 30 seconds 
angioplasty balloon 
inflations/deflations  
118 
 
9% reduction in MI size 
at 3 months by CMR 
31% increase in 
myocardial salvage 
index 
First study to report 
cardioprotective 
effects of IPost in 
PPCI patients using 
CMR 
 
Thuny et al 86 Four x 60 seconds 
angioplasty balloon 
inflations/deflations  
50 
 
40% reduction in MI 
size and 21% reduction 
in myocardial oedema 
on CMR 
 
First study to report 
effect of IPost on 
myocardial oedema 
on CMR 
 
Engstrom et al  
DANAMI-3 
ClinicalTrials.go
v Identifier: 
NCT01435408 
 
Four x 30 seconds 
angioplasty balloon 
inflations/deflations 
2000 
Completed 
recruitment 
All-cause mortality, 
heart failure at 4 years 
Results awaited 
First study which will  
report effects of IPost 
on long-term clinical 
outcomes 
Remote ischaemic conditioning in STEMI patients 
 
Botker et al 
201055  
Four x 5 minutes upper 
arm cuff 
inflations/deflations in the 
ambulance prior to PPCI 
 
142 
 
Increase in myocardial 
salvage index at 30 
days 
No difference in MI size 
(SPECT or peak 
Troponin) 
 
First study to test 
effect of RIC in PPCI-
treated STEMI 
patients. Reduced MI 
size in LAD STEMI. 
Rentoukas et al 
201056  
Three x 4 minutes cuff 
inflations/deflations at the 
hospital prior to PPCI 
 
93  
 
Better ST resolution 
and lower peak 
Troponin I. Synergistic 
effects with morphine. 
 
 
Crimi et al 
201358 
Three x 5 minutes thigh 
cuff inflations/ deflations 
at onset of reperfusion 
100 anterior 
STEMI  only 
20% reduction in 72 
hours AUC CK-MB.  
% reduction in 
myocardial oedema by 
CMR 
 
First study to show 
effect of RIC given at 
onset of reperfusion 
via PPCI. Also, first 
study to report effect 
of RIC on enzymatic 
MI size and 
myocardial oedema. 
 
White et al 
201457 
Four x 5 minutes upper 
arm cuff 
inflations/deflations at the 
hospital prior to PPCI 
 
197 27% reduction in MI 
size by CMR 
19% reduction in 
myocardial oedema by 
CMR 
 
First study to show 
effect of RIC given 
prior to PPCI on MI 
size and myocardial 
oedema by CMR 
Hausenloy et al  
ERIC-LYSIS 
Four x 5 minutes upper 
arm cuff 
519 17% reduction in 
enzymatic MI size (CK-
Only study to test 
effect of RIC in 
26 
 
(ClinicalTrials.g
ov Identifier: 
NCT02197117) 
 
inflations/deflations at 
hospital prior to 
thrombolysis 
MB and Trop-T) 
 
thrombolysed STEMI 
patients 
Sloth et al 
201487 
 
Four x 5 minutes upper 
arm cuff 
inflations/deflations in the 
ambulance prior to PPCI 
 
251 51% reduction in  all-
cause mortality, 
nonfatal MI, TIA or 
stroke, HHF at 3.8 
years 
First study to test 
effect of RIC on long-
term outcomes 
following PPCI 
 
Botker  
CONDI-2 
Hausenloy 
ERIC-PPCI 
 
ClinicalTrials.go
v Identifier: 
NCT01857414 
Four x 5 minutes upper 
arm cuff 
inflations/deflations prior 
to PPCI 
 
4300 
ongoing  
Primary endpoint of 
cardiac death and HHF 
at 12 months 
Collaboration 
between UK, 
Denmark. First study 
to test effect of RIC 
on long-term clinical 
outcomes at primary 
endpoint following 
PPCI 
IPost: Ischaemic postconditioning; RIC: remote ischaemic conditioning; STEMI: ST-segment elevation myocardial infarction; AUC: area 
under curve; CK: creatine kinase; PPCI: primary percutaneous coronary intervention; CK-MB: creatine kinase MB isoenzyme; SPECT: 
single-photon emission computed tomography; LVEF: left ventricular ejection fraction; PPCI: primary percutaneous coronary 
intervention; MI: myocardial infarct; LAD: left anterior descending artery; CMR: cardiovascular magnetic resonance imaging; Trop I: 
Troponin I; TIA: transient ischaemic attack; HHF: hospitalisation for heart failure; 
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Table 4: Major clinical studies investigating promising pharmacological conditioning 
agents in STEMI patients 
Clinical study Therapeutic 
intervention 
 
Number Outcome Potential mechanisms 
underlying cardioprotection 
Kitakaze et al 
200761 
J-WIND 
  
 72 hours IV 
carperitide (atrial 
natriuretic peptide 
analogue) infusion 
started prior to PPCI 
 
569 
 
15% reduction in 72 hours 
AUC total CK  
2.0% absolute increase in 
LVEF 
Atrial natriuretic peptide 
targets pro-survival kinase 
pathways such as the cGMP 
and RISK pathways 
Piot et al 200862 
 
IV cyclosporin A 
(2.5mg/kg) bolus 10 
minutes prior to PPCI 
58 
 
44% reduction in MI size (72 
hours AUC total CK) 
20% reduction in MI size (CMR 
subset) 
 
28% reduction in MI size and 
smaller LVESV on CMR at 6 
months88 
 
Cyclosporin-A inhibits the 
opening of the mitochondrial 
permeability transition pore, a 
critical determinant of lethal 
myocardial reperfusion injury 
Lonborg et al 
201263  
IV infusion of 
exenatide started 15 
minutes prior to PPCI 
and continued for 6 hr 
 
107  
 
Increase in myocardial salvage 
index (0.62 to 0.71) 
23% reduction in MI size at 3 
months on CMR 
 
Patients presenting with short 
ischaemic times (≤132 
minutes) had greater 
myocardial salvage89  
 
Exenatide, a GLP-1 analogue, 
targets pro-survival kinase 
pathways such as the RISK 
pathway 
Ibanez et al 
201364 
IV metoprolol (3x5mg) 
in ambulance prior to 
PPCI 
270 Reduction in MI size by CMR 
at one week. Increased LVEF 
at 6 months 
Improvement in clinical 
outcome at 2 years 
 
Reduced: incidence of severely 
depressed LVEF (<35%) at 6 
months by 60%; less need for 
ICD by 65% at 6 months and 
reduced HF at 2 years 90 
The mechanism of 
cardioprotection is not 
currently clear 
STEMI: ST-segment elevation myocardial infarction; IV: intravenous; AUC: area under curve; CK: creatine kinase; LVEF: left ventricular 
ejection fraction; cGMP: cyclic guanosine monophosphate; RISK: reperfusion injury salvage kinase; MI: myocardial infarct; CMR: 
cardiovascular magnetic resonance imaging; LVESV: left ventricular end-systolic volume; GLP-1: glucagon-like peptide-1; AAR: area at 
risk; HF: heart failure 
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Table 5: Improving the translation of cardioprotection for patient benefit 
 STEMI-PPCI trials Cardiac bypass surgery trials 
Patient 
selection 
Select patients which are most likely to 
benefit from the cardioprotective therapy: 
 
1. Large AAR (>30% of the left ventricle) 
2. No coronary collateralisation (Rentrop<1) 
3. Fully occluded artery prior to PPCI 
(TIMI<1) 
4. Onset of symptoms 3-6 hours  
Select patients which are most likely to benefit 
from the cardioprotective therapy: 
 
1. Patients undergoing on-pump cardiac 
surgery who are subjected to global acute 
IRI. 
2. Patients with longer cardiopulmonary 
bypass times are at greater risk of 
perioperative myocardial injury. 
3. Higher risk patients who are at greater 
risk of perioperative myocardial injury. 
 
Confounding 
factors 
Be aware of confounding factors such as 
prior chest pain, age, diabetes mellitus, 
hypertension, hyperlipidaemia and 
concomitant medication (nitrates, morphine), 
which can interfere with cardioprotection.  
Be aware of confounding factors such as prior 
chest pain, age, diabetes mellitus, 
hypertension, hyperlipidaemia and 
concomitant medication (sulphonylureas, 
nitrates, morphine, nicorandil, volatile 
anaesthetics), which can interfere with 
cardioprotection. 
 
The 
intervention  
1. Only test therapies having shown 
conclusive cardioprotection in pre-
clinical studies. 
2. Administer the therapy prior to 
myocardial reperfusion via PPCI. 
 
1. Only test therapies having shown 
conclusive cardioprotection in pre-clinical 
studies 
2. Option to administer therapy prior to 
surgical incision, in cardioplegic solution, 
or at time of aortic declamping. 
 
Clinical 
endpoints 
Select relevant clinical endpoints for 
assessing cardioprotective efficacy: 
 
1. MI size (enzymatic or CMR) 
2. Myocardial salvage index (more 
sensitive than MI size reduction) 
3. Microvascular obstruction 
4. LV remodelling (LVH, LVEF and indexed 
LVEDV or LVESV) 
5. Cardiac death  
6. Hospitalisation for heart failure. 
Select relevant clinical endpoints for 
assessing cardioprotective efficacy: 
 
1. Perioperative myocardial injury 
(enzymatic or CMR) 
2. LVEF 
3. Amount of inotrope support required 
4. Cardiac death  
5. Hospitalisation for heart failure 
 
STEMI: ST-elevation myocardial infarction; PPCI: percutaneous coronary intervention; AAR: area at risk; CMR: cardiovascular magnetic 
resonance imaging; AUC: area under the curve; MI: myocardial infarction, LVH: left ventricular hypertrophy; LVEF: left ventricular 
ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume 
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Figure 1 
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Figure 2 
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Ischaemic conditioning in the clinical setting: key points 
 
 
 ‘Ischaemic conditioning’ has the therapeutic potential to protect the heart against 
acute ischaemia/reperfusion (I/R) injury and improve clinical outcomes in patients 
with ischaemic heart disease (IHD), the leading cause of death and disability 
worldwide.   
 Ischaemic conditioning is mediated by applying cycles of brief ischaemia and 
reperfusion to either the heart itself or to an organ/tissue remote from the heart - it 
can be reproduced by certain pharmacological agents (termed ‘pharmacological 
conditioning’). 
 Ischaemic and pharmacological conditioning have been reported in proof-of-
concept studies to be beneficial in three major clinical settings in which the heart is 
subjected to acute I/R injury: cardiac bypass surgery, elective percutaneous 
coronary intervention (PCI), and ST-segment elevation myocardial infarction 
(STEMI) patients treated by primary PCI.       
 Whether this therapeutic strategy can improve patient outcomes in these clinical 
settings should be known in the next few years with the availability of results from 
several large multi-centre clinical trials. 
 The translation of promising cardioprotective therapies discovered in the research 
laboratory into the clinic has been hampered by the use of inadequate animal 
models and poorly designed clinical studies – this can be overcome by increased 
interaction between basic scientists and clinicians, thereby facilitating the translation 
of novel cardioprotective therapies into the clinical setting for patient benefit. 
